Cerep SA and Xenometrix Inc. Announce Strategic Partnership for Gene Expression Profiling

Strategic Insights -

Cerep SA, a French drug discovery company, has signed an agreement with Xenometrix Inc., a US biotechnology company, granting Cerep access to Xenometrix's technology for gene expression profiling. This partnership will enable Cerep to investigate gene response profiles of compounds, increasing efficiency and lowering costs in drug lead optimization. The license is non-exclusive and covers a range of technologies, including proteomics and high-density probe arrays.

Key Takeaways:

  • Cerep SA has signed a license agreement with Xenometrix Inc. for gene expression profiling technology.
  • The license is non-exclusive and covers various technologies, including proteomics and high-density probe arrays.
  • Cerep will use the technology to investigate gene response profiles of compounds, focusing on toxicity and drug lead optimization.
  • The partnership is a major step forward for Cerep in maintaining its leadership position in pharmacological profiling.
  • Cerep's CEO, Thierry Jean, stated that the technology fits nicely with Cerep's current strategy based on high-throughput hit selection systems.
  • Cerep has created a profitable business model based on the supply of combinatorial libraries and pharmacological profiling services to over 100 pharmaceutical laboratories worldwide.
  • Cerep completed its IPO on the Nouveau Marche in February, raising $15 million, and received an equity investment of $3.7 million from Sanofi.

Statistics:

  • $15 million: the amount raised by Cerep SA in its IPO on the Nouveau Marche.
  • $3.7 million: the equity investment received by Cerep from Sanofi.
  • FF225: the IPO price of Cerep's shares.
  • 100: the number of pharmaceutical laboratories worldwide that Cerep supplies with combinatorial libraries and pharmacological profiling services.

Sources:

  • Cerep SA. (June 1998). Cerep SA and Xenometrix Inc. Announce Strategic Partnership for Gene Expression Profiling. PR Newswire.
  • PR Newswire. (June 1998). Cerep SA and Xenometrix Inc. Announce Strategic Partnership for Gene Expression Profiling.
  • Cerep SA. (February 1998). Cerep SA Completes Initial Public Offering (IPO) on Nouveau Marche.
  • Xenometrix Inc. (January 1998). Xenometrix Inc. Expands Gene Response Profiling Capabilities. PR Newswire.